How “Disease-Agnostic” CRISPR and Baby KJ Are Changing the World

Date: September 23, 2025

Executive Summary

Two breakthroughs in gene editing are rewriting the biotech playbook this year. A “disease-agnostic” approach promises to create therapies that can treat multiple disorders using the same toolkit, while the story of Baby KJ, a newborn treated with a personalized CRISPR therapy, shows that individualized medicine can move from concept to reality in a matter of months. Together, these advances could change how entrepreneurs, investors, and businesses think about biotech, from drug development timelines to new startup models.

The Full Article

For years, gene editing has carried the aura of science fiction, a bold idea that one day we might be able to fix DNA like a typo in a document. In 2025, the field feels less like a distant dream and more like a tectonic shift under way. Two stories stand out: the rise of a new “disease-agnostic” model for gene therapies, and the remarkable case of Baby KJ, a child whose life was transformed by a therapy designed specifically for him in record time.

Let’s start with Baby KJ. Born with CPS1 deficiency, a rare condition that prevents the liver from processing ammonia, KJ’s future was grim. Traditional treatments are limited and often precarious, some patients rely on harsh diets and medications, while others require liver transplants with uncertain outcomes. But KJ’s doctors, working with CRISPR researchers, took a different path. They crafted a therapy tailored to his exact mutation, using base editing, a refined form of CRISPR that makes precise changes without fully cutting DNA strands. In only six months, they moved from design to infusion. The results so far are nothing short of astonishing: ammonia levels have stabilized, his dependency on medication has eased, and his quality of life has improved dramatically. The long-term safety still needs to be proven, but for the first time, a personalized CRISPR therapy has shown what’s possible in real time.

In Cambridge, Massachusetts, another breakthrough is taking shape in David Liu’s lab. Liu and his team have refined base editing and prime editing into what they call a “disease-agnostic” framework. Instead of developing a therapy from scratch for each mutation, a costly and time-consuming process, they’re building a system that can be adapted across multiple conditions. Think of it less like designing a brand-new car for every road, and more like creating a versatile chassis that can handle highways, dirt paths, and mountain trails with minor adjustments. If successful, this approach could collapse years of R&D into months and make rare diseases commercially viable to treat.

For businesses, these shifts open a new frontier. In the past, biotech startups often had to bet everything on a single disease, hoping their one therapy would survive the regulatory gauntlet. Now, we may see companies built around platforms rather than single products, startups focused on delivery systems, monitoring tools, or modular editing kits that plug into many therapies. Investors, too, are watching closely. The risk profile changes dramatically when timelines shrink and scalability increases. What once looked like a moonshot begins to resemble a pipeline.

Of course, every breakthrough carries baggage. Personalized therapies like KJ’s are expensive, and scaling them will challenge healthcare systems already strained by cost. Regulatory agencies are still catching up, questions about off-target effects, long-term monitoring, and ethical use remain unresolved. The patent landscape, already complicated in CRISPR’s first wave, could become even more tangled as companies jockey for control over base and prime editing technologies. And while “disease-agnostic” sounds elegant, proving that a therapy is safe across diverse patient populations will take time and enormous data.

Still, it’s hard to ignore the momentum. The combination of faster timelines, precision tools, and broader applicability is the kind of shift that creates entirely new industries. Delivery mechanisms, manufacturing platforms, regulatory compliance software, and even AI-driven genetic diagnostics are ripe for entrepreneurial innovation. For founders, the opportunity isn’t just in making therapies, it’s in building the infrastructure, tools, and services that will make the gene-editing era possible.

Gene editing has entered a new chapter. Personalized therapies like the one that saved Baby KJ show what’s possible when innovation moves fast, while disease-agnostic approaches hint at a scalable future where treatments aren’t limited to a handful of conditions. For entrepreneurs, this is the moment to pay attention: whether you’re in biotech or building adjacent tools, the future of healthcare is being rewritten, and it’s happening now.